Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-220 in chronic cutaneous sarcoidosis
NCT02192489Phase 2Withdrawn
- Sponsor
- Celgene Corporation
- Start
- Nov 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of iberdomide in sarcoidosis (3 arms), sponsored by Celgene Corporation. Primary endpoint: Number of participants with adverse events up to 12 weeks. Planned start Nov 2014; status: withdrawn.
02
Drugs
iberdomide
03
Conditions
sarcoidosis
Beyond the preview
Go deeper on NCT02192489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02192489.